Despite the availability of highly active agents against HCV, HIV-infected patients require special considerations for drug interactions when considering treatment options.
A new method assessing the influenza A strain provides investigators with a more detailed look at influenza viruses.
Traditional therapy coverage does not include recent data that offers some updates in evaluating the current effectiveness of empiric antibiotic treatment.
Elevated beta-lactam concentrations have been associated with neurotoxic adverse effects, including seizures and mental status changes.
Even if HIV-positive individuals have a low-to-moderate risk for cardiovascular disease, they still experience more coronary plaque.
EVD outbreaks this year serve as a reminder of the virus’ severity and the importance of having a containment strategy in place.
As the number of COVID-19 cases continues to rise, oral treatment options for at-home use are in demand to provide early intervention and reduce the progression to severe disease, hospitalization, and death.
Findings increasingly suggest the mortality risk may be reduced by initiating daptomycin within 3 days of infection.
Infectious disease outbreaks will continue to increase and trying to find strategies to ensure providers are cared for to prevent burnout and shortage staffing is essential if another pandemic arises.
Will there be an answer to keep the continuously evolving virus at bay? Are seasonal combination vaccines the wave of the future?
Herpes simplex viruses are chronic infections that underscore racial and ethnic disparities and are afflicting adolescents in increasing numbers.
The federal agency recommends using either PCV13 or PCV15 as part of a 4-dose series for pediatric patients between the ages of 2-59 months.
In the latest column from SIDP, handshake stewardship prioritizes face-to-face communication between frontline providers to enable feedback to assess the appropriateness of prescribed antimicrobials.
This nitroimidazole antibiotic is shown to be efficacious for this condition.
Although there are challenges for clinical and infectious disease pharmacists when trying to apply this concept, here are some considerations and strategies to employ stewardship in this setting.
The 340B program has had a great impact on access to HIV treatment and prevention services in the US.
According to a small study, the Moderna and Pfizer COVID-19 vaccines do not impact male fertility.
A multidisciplinary panel concludes a discussion on best practices for managing patients with HIV in various healthcare settings and overcoming social health disparities.
Key opinion leaders provide some advice for the public regarding COVID-19 booster shots and look to the future of the pandemic.
More treatment options and modalities are now available for patients.
Risk of inaccuracy with pulse oximeters and clinician knowledge gaps in people of color may affect sepsis evaluations and impact treatment plans.
George Loukatos, MD, shares clinical pearls for the management of the SARS-CoV-2 and influenza viruses.
This pathogen is the third most frequently isolated nontuberculous mycobacteria seen in the United States. Here is a review of how it presents and treatment options.
The increasing presence of multiple non-AIDS comorbidities in women and others living with HIV challenges clinicians to steer away from the approach of optimizing individual chronic conditions but to think more holistically.
A research agenda focusing on breakthrough infections, reinfections, severity, and sequelae is needed to inform clinical practice when COVID-19 emphasis shifts from eradication to living with the disease.
Since the vancomycin guideline update, institutional leaders have been faced with the challenge of implementing and monitoring AUC-guided dosing.